Abstract:Background: Cancer immune evasion remains a major barrier in developing enduring therapies for epithelial ovarian cancer (EOC). Expression of programmed death-ligand 1 (PD-L1) is known for its immunosuppressive role in cancer, thus interferences to PD-L1 have shown marked efficacy against many advanced cancers. However, the mechanisms by which PD-L1-negative cancers evade immune response remain unelucidated. We have found chemokine (C-C motif) ligand 5 (CCL5) and (C-X-C motif) ligand 10 (CXCL10) to up-regulate in PD-L1-negative EOC. Therefore, the present study aims to investigate blockade of CCL5/CXCL10 signaling to overcome immune evasion of EOC. Methods: Isogenic BRCA2-mutated PEO1 and BRCA2-wild type PEO4 EOC cells were treated with IFNγ, olaparib, or both in combination for western blot and flow cytometric analyses of PD-L1 expression. The conditioned medium of PEO1 and PEO4 cells was analyzed for immune array analysis to determine and compare the levels of 36 cytokines. PEO1 and PEO4 cells were co-cultured with CD3/CD28 antibodies-activated human peripheral blood mononuclear cells (PBMCs). Then, PBMCs were stained with anti-CD8 or CD4 and CD25 antibodies for flow cytometric analyses of cytotoxic or helper T cells, respectively. PEO1 and PEO4 cells were co-cultured with activated PBMCs in the presence and absence of TAK-779 or AMG-487. Thereafter, PBMCs were stained with anti-CD4, CD25, and FOXP3 antibodies for flow cytometric analyses of regulatory T cells (Tregs). PEO1 and PEO4 cells were transfected with CCL5- or CXCL10-siRNA and subsequently co-cultured with activated SUPT1 cells or PBMCs. The conditioned medium was collected and analyzed for the levels of IFNγ by ELISA. Results: PEO1 cells exhibited an up-regulation of basal and IFNγ-induced PD-L1 compared with PEO4 cells. PEO4 cells displayed a pronounced increase in the CCL5 and IFNγ-induced CXCL10 compared with PEO1 cells. Co-culture of PBMCs with PEO1 and PEO4 cells led to a significant decrease in activated CD8+ effector T and CD4+ helper T cells. However, co-culture of PBMCs with PEO4 cells caused a significant increase in activated CD4+ helper T cells. Co-culture of PBMCs with PEO4 cells caused a significant increase in FOXP3+CD4+CD25+ Tregs. This increase in Tregs was significantly reduced by the treatment with the CCL5/CCR5 antagonist TAK-779 or the CXCL10/CXCR3 antagonist AMG-487. Silencing of CCL5 or CXCL10 in PEO4 cells by siRNA significantly increased IFNγ production by SUPT1 cells and PBMCs. Conclusions: PEO4 cells secrete CCL5 and IFNγ-induced CXCL10 to activate Tregs, enabling tumor cells to evade host immune response by dysregulating their microenvironment. PEO4 cells-induced Tregs are reduced by CCL5/CXCL10 signaling blockade with TAG-779 or AMG-487. Furthermore, silencing of CCL5 or CXCL10 in PEO4 cells with siRNA abolishes Treg-mediated immunosuppression and restores the antitumor activity of effector T cells. Citation Format: Annabelle C. Lin, Jake Moscarelli, Z. Ping Lin, Elena S. Ratner. Blockade of CCL5 and CXCL10 signaling as a novel immunotherapy for epithelial ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 100.

Atractylenolide I Modulates Ovarian Cancer Cell-Mediated Immunosuppression by Blocking MD-2/TLR4 Complex-Mediated MyD88/NF-κB Signaling in Vitro

Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent Pathway

Atractylenolide-I suppresses tumorigenesis of breast cancer by inhibiting toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway

Immunomodulatory Activity of 3 Beta,6 Beta-Dihydroxyolean-12-En-27-Oic Acid in Tumor-Bearing Mice

Atractylenolide-I Suppresses Tumorigenesis of Breast Cancer by Inhibiting Toll-Like Receptor 4-Mediated Nuclear Factor-B Signaling Pathway

Atractylenolide II Suppresses Glycolysis and Induces Apoptosis by Blocking the PADI3-ERK Signaling Pathway in Endometrial Cancer Cells

Abstract 100: Blockade of CCL5 and CXCL10 signaling as a novel immunotherapy for epithelial ovarian cancer

Aloe-Emodin Induces Breast Tumor Cell Apoptosis Through Upregulation of Mir-15A/mir-16-1 That Suppresses BCL2

IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation

Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway

Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.

Atractylenolide I inhibited the development of malignant colorectal cancer cells and enhanced oxaliplatin sensitivity through the PDK1-FoxO1 axis

ERK inhibition sensitizes cancer cells to oleanolic acid-induced apoptosis through ERK/Nrf2/ROS pathway

Atractylodin induces oxidative stress‐mediated apoptosis and autophagy in human breast cancer MCF‐7 cells through inhibition of the P13K/Akt/mTOR pathway

Inhibition of Ca2+ -Activated Chloride Channel ANO1 Suppresses Ovarian Cancer Through Inactivating PI3K/Akt Signaling.

Atractylenolide I Inhibits NLRP3 Inflammasome Activation in Colitis-Associated Colorectal Cancer via Suppressing Drp1-Mediated Mitochondrial Fission

Eriodictyol regulated ferroptosis, mitochondrial dysfunction, and cell viability via Nrf2/HO‐1/NQO1 signaling pathway in ovarian cancer cells

A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGFβ and FAK Pathways

An Endogenous Aryl Hydrocarbon Receptor Ligand Inhibits Proliferation and Migration of Human Ovarian Cancer Cells

Transcriptome Study of Oleanolic Acid in the Inhibition of Breast Tumor Growth Based on High-Throughput Sequencing.

Eupalinolide O, a Novel Sesquiterpene Lactone from Eupatorium Lindleyanum DC., Induces Cell Cycle Arrest and Apoptosis in Human MDA-MB-468 Breast Cancer Cells.